Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)

Capital Medical University

Status and phase: Unknown; Early Phase 1

Conditions: Hepatocellular Carcinoma

Treatments: Drug: Fu Zheng Jie Du Hua Yu therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT05152498

BeijingDH-YZY

Details and patient eligibility

About

The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.

Enrollment: 142 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meet the criteria of hepatocellular carcinoma
• Ages Eligible for Study: ≤75 years old;
• Informed consent from the patient.

Exclusion criteria

• Serious problem of heart, lung, or kidney with severe dysfunction;
• Pregnant or child breast feeding women;
• Mental or cognitive disorders;
• Participating in other drug trials;
• Who are allergic to the study drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

142 participants in 2 patient groups

Fu Zheng Jie Du Hua Yu therapy

Experimental group

Treatment:

Drug: Fu Zheng Jie Du Hua Yu therapy

Routine medical care

Experimental group

Treatment:

Drug: Fu Zheng Jie Du Hua Yu therapy